Join

Compare · ANVS vs NVS

ANVS vs NVS

Side-by-side comparison of Annovis Bio Inc. (ANVS) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ANVS and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $272.75B, about 2459.5x ANVS ($110.9M).
  • Over the past year, ANVS is up 23.8% and NVS is up 26.0% - NVS leads by 2.2 points.
  • ANVS has been more active in the news (5 items in the past 4 weeks vs 1 for NVS).
  • NVS has more recent analyst coverage (25 ratings vs 4 for ANVS).
PerformanceANVS+23.83%NVS+26.04%
2025-04-30+0.00%2026-04-29
MetricANVSNVS
Company
Annovis Bio Inc.
Novartis AG
Price
$1.84-1.34%
$143.01-1.71%
Market cap
$110.9M
$272.75B
1M return
-7.29%
-4.89%
1Y return
+23.83%
+26.04%
Sector
Health Care
Health Care
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
AMEX
NYSE
IPO
2020
News (4w)
5
1
Recent ratings
4
25
ANVS

Annovis Bio Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

Latest ANVS

Latest NVS